Exhibitor

Nabriva is a biopharmaceutical company engaged in research and development of novel antibiotics to treat serious infections. Nabriva is developing its lead product candidate, lefamulin, as the first pleuromutilin for IV/oral administration in humans. Lefamulin is currently in Phase 3 development for the treatment of community-acquired bacterial pneumonia (CABP) in adults. In September 2017, top-line data from the first of 2 trials demonstrated lefamulin met all primary FDA and EMA endpoints with favorable tolerability.